Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLCO1B1 | Q9Y6L6 | 8/20 | 0.67 |
| ▸ | ABCB11 | O95342 | 3/20 | 0.53 |
| ▸ | LPAR1 | Q92633 | 7/20 | 0.43 |
| ▸ | ABCC3 | O15438 | 2/20 | 0.36 |
| ▸ | ABCC4 | O15439 | 2/20 | 0.36 |
| ▸ | SLCO1B3 | Q9NPD5 | 2/20 | 0.36 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | APP | P05067 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22256930 | 0.90 | SLCO1B1 (0.53) | SLCO1B1ABCB11MEN1KMT2AAPP | |
| SCHEMBL22256657 | 0.89 | SLCO1B1 (0.54) | SLCO1B1ABCB11LPAR1PTPN1MEN1 | |
| SCHEMBL24287896 | 0.89 | SLCO1B1 (0.54) | SLCO1B1ABCB11LPAR1PTPN1MEN1 | |
| SCHEMBL22256654 | 0.89 | SLCO1B1 (0.54) | SLCO1B1ABCB11LPAR1PTPN1MEN1 | |
| SCHEMBL24042962 | 0.83 | SLCO1B1 (0.45) | SLCO1B1ABCB11KMT2A | |
| SCHEMBL24043036 | 0.83 | SLCO1B1 (0.67) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 | |
| SCHEMBL22256882 | 0.83 | SLCO1B1 (0.67) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 | |
| SCHEMBL24043052 | 0.82 | SLCO1B1 (0.64) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 | |
| SCHEMBL22256875 | 0.82 | SLCO1B1 (0.64) | SLCO1B1ABCB11LPAR1ABCC3ABCC4 | |
| SCHEMBL24042784 | 0.82 | SLCO1B1 (0.43) | SLCO1B1ABCB11MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2025-08-05 | — | — | US | disclosed |
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2022-03-17 | — | — | US | disclosed |
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO., LTD. (CN) | 2022-03-17 | — | — | US | disclosed |
| EP-3912975-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | Wuhan LL Science And Technology Development Co., Ltd. (CN) | 2021-11-24 | — | — | EP | disclosed |
| WO-2020147739-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONISTS AND PREPARATION METHOD THEREFOR | 武汉朗来科技发展有限公司 | 2020-07-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12377083-B2 | Lysophosphatidic acid receptor antagonist and preparation method therefor | LPAR1, LPAR2, LPAR4 | SLCO1B1 3685/4885ABCB11 3552/4885LPAR1 1/4885 |
| US-20220079928-A1 | LYSOPHOSPHATIDIC ACID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | LPAR1, LPAR2, LPAR4 | SLCO1B1 3685/4885ABCB11 3552/4885LPAR1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.